# AOD 9604 dosage & reconstitution (10 mg vial)

AOD 9604 dosage: calculations for a 10 mg vial use the same amounts described in the literature. Adding 2 mL of bacteriostatic water produces 5 mg/mL, so each U-100 unit contains 50 mcg.

- **Vial contents:** 10 mg AOD 9604
- **Final volume:** 2 mL
- **Concentration:** 5 mg/mL
- **One U-100 unit:** 50 mcg in 0.01 mL

## Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing

### Standard / Gradual Approach (2 mL = ~5 mg/mL)

| Week / phase | Daily dose | Units per injection (mL) |
|---|---|---|
| Weeks 1–4 | 300 mcg | 6 units (0.06 mL) |
| Weeks 5–12 | 500 mcg | 10 units (0.10 mL) |

Frequency: Once daily, subcutaneously, at a consistent time.

### Reconstitution Steps

1. Draw 2 mL of bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid shaking to prevent foaming.
3. Gently swirl or roll until fully dissolved (clear solution).
4. Label with the reconstitution date and refrigerate at 2–8 °C, protected from light; use within 4 weeks.

Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

## U-100 Conversion Table

| U-100 units | Volume | Contains | Yield per vial |
|---|---|---|---|
| 2 | 0.02 mL | 100 mcg | 100 injections |
| 5 | 0.05 mL | 250 mcg | 40 injections |
| 10 | 0.10 mL | 500 mcg | 20 injections |
| 20 | 0.20 mL | 1 mg (1000 mcg) | 10 injections |
| 30 | 0.30 mL | 1.5 mg (1500 mcg) | 6 injections |
| 50 | 0.50 mL | 2.5 mg (2500 mcg) | 4 injections |
| 100 | 1.00 mL | 5 mg (5000 mcg) | 2 injections |

## Supplies Needed

**AOD 9604 vials (10 mg each)**
- Standard / Gradual Approach, 12 weeks: Minimum 4 vials (36.4 mg required).
- Standard / Gradual Approach, 24 weeks: Minimum 8 vials (78.4 mg required).

**U-100 syringes (1 mL)**
- Standard / Gradual Approach, 12 weeks: 84 new syringes for 84 injections.
- Standard / Gradual Approach, 24 weeks: 168 new syringes for 168 injections.

**Bacteriostatic water**
- Standard / Gradual Approach, 12 weeks: 8 mL total (2 mL per vial) → 3 × 3 mL vials.
- Standard / Gradual Approach, 24 weeks: 16 mL total (2 mL per vial) → 6 × 3 mL vials.

**Alcohol swabs**
- Standard / Gradual Approach, 12 weeks: 168 minimum; one box of 100 does not cover the calculation.
- Standard / Gradual Approach, 24 weeks: 336 minimum; one box of 100 does not cover the calculation.

## Storage Instructions

- Lyophilized (unopened): −20 °C for long-term storage; 2–8 °C if used within weeks. Protected from light.
- Reconstituted: 2–8 °C, do not freeze. Use within the documented period (typically up to 4 weeks with bacteriostatic water).
- Handling: do not shake; avoid temperature cycling; label with date and concentration.
- Discard: cloudy solutions, particulates or expired preparations are discarded.

## How This Works

AOD-9604 (Advanced Obesity Drug) is a modified synthetic peptide representing the C-terminal fragment (amino acids 176-191) of human growth hormone (hGH), with a tyrosine modification at position 177. This 16-amino-acid fragment (MW: 1815.1 Da) selectively retains the lipolytic properties of hGH without effects on IGF-1 receptors or growth. Structure and Modifications: Base sequence: hGH 176-191 Modification: Tyr-hGH fragment (177-191) Addition: stabilizing N-terminal dipeptide Net charge: +2 (basic residues) Hydrophilicity: high aqueous solubility Selective Lipolytic Mechanisms: Lipolysis Activation without GH Receptor: The classic GH receptor is not joined. (domain 176–191 is insufficient) IGF-1-independent mechanism: no growth/anabolic effects Direct lipolysis: hormone-sensitive lipase (HSL) activation Perilipin: phosphorylation and release of lipase access to triglycerides Lipid Metabolism Modulation: β-Oxidation: 35-45% increase in mitochondrial fatty acid oxidation CPT-1 (carnitine palmitoyltransferase): upregulation of FA entry into mitochondria Lipogenesis: inhibition of new fat synthesis (↓ acetyl-CoA carboxylase) Gene expression: modulation of PPARα, PGC-1α (metabolism…

## Research FAQ

**Does AOD-9604 cause GH-like effects (growth, IGF-1)?** R: No. Critical distinction:
**P: What is the optimal administration timing for maximum lipolysis?** R: Fasted morning workout It is optimal:
**Q: Is it effective orally?** Peptide susceptible to degradation by digestive enzymes
**Q: Synergistic combinations for body composition?** R: Studied combinations with additive effects:
**Q: Common side effects in animal models?** R: Excellent safety profile:
**P: Desensitization or tachyphylaxis?** R: La literatura la describe como mínima:
**Q: Biomarkers to monitor effectiveness?** Body composition: DEXA (baseline, 4, 8, 12 weeks), waist circumference

## References

1. Modelos preclínicos en roedor
2. Heffernan M, et al. (2001) “The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta3-AR knock-out mice” – Endocrinology 142(12):5182-5189. [PubMed: 11713213]
3. Ng FM, et al. (2000) “Growth hormone fragment 176-191 stimulates lipolysis and inhibits lipogenesis in vitro” – J Endocrinol 166(1):145-150. [PubMed: 10856893]
4. Munday MR, et al. (2001) “Addition of a C-terminal ‘Tyr-tag’ to the hGH fragment 177-191 produces a highly potent orally active lipolytic agent” – FEBS Lett 488(1-2):49-53. [PubMed: 11163794]
5. Heffernan MA, et al. (2000) “Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment” – Int J Obes Relat Metab Disord 24(10):1442-1448. [PubMed: 11126341]
6. Leung KC, et al. (2002) “Growth hormone (GH) secretagogue, AOD-9604, increases lipolysis and decreases body fat in obese subjects” – Obesity 10(S8):102S. [Abstract]
7. Ng FM, et al. (2011) “AOD9604, a synthetic lipolytic peptide, does not affect glucose metabolism” – Clinical and Experimental Pharmacology and Physiology 38(12):897-903. [PubMed: 21883414]
8. Khajavi M, et al. (2003) “AOD9604 stimulates chondrocyte proliferation and cartilage production in vitro and in vivo” – Osteoarthritis Cartilage 11(Suppl A):S74.

---
Source: https://protocolopeptidos.com/en/compuestos/aod-9604-10-mg · Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.